Mitigator efficacies after realistic improvised nuclear device (IND) exposure: merie - the need for improved radiation effect mitigators stems from the significant probability of the detonation of…

Active Project Grant Awarded Last action

Award ID
P01AI186817
Recipient
Awarding agency
Obligated
$6,444,030

Award facts

Assistance listing
93.310 Trans-NIH Research Support
Completion date 24% complete
Funding agency
Office of the Director National Institutes of Health, Department of Health and Human Services
Place of performance
New York, NY 10032, USA

Award details come from USAspending.gov.

Description

Mitigator efficacies after realistic improvised nuclear device (IND) exposure: merie - the need for improved radiation effect mitigators stems from the significant probability of the detonation of an improvised nuclear device (IND). Typically pharmaceutical radiation countermeasures have been tested against x rays delivered over a few minutes. In practice, however, 1) the majority of the IND-related radiation dose will be delivered by "direct" radiation from the IND, over a time period of less than a microsecond, and 2) a significant component (10 - 50%) of the biological effect from a ground-burst IND will be from fission neutrons. The biological effects and associated mechanisms from these IND-specific radiations are typically quite different as compared with the corresponding effects and mechanisms associated with conventional x rays delivered over a few minutes. In addition there is evidence that mitigator performance is different for these IND- specific radiation types. IT is therefore important to understand whether radiation countermeasures that have been developed and tested against x rays delivered over time periods of a few minutes will also be effective in these more realistic IND exposure scenarios. At columbia university unique radiation sources are available to simulate each of these IND-specific exposures. These tools will allow each of the research projects to address the same common research themes: 1. Are radiation mitigators that were developed and tested with x rays irradiated over a few minutes, also effective against a) very short, very high dose rate radiation exposures, b) IND-specific neutrons? 2. Using these realistic IND exposures, can mitigators developed for specific endpoints have utility for other key radiobiological endpoints? 3. Using these realistic IND exposures, can combining multiple mitigators that were each designed for specific endpoints, have increased overall utility if given in combination ("polypharmacy")? In this highly synergistic proposal, the projects and cores are tightly linked by common research themes and hypotheses, by a shared animal model, and by shared samples and data. The WAG/rijcmcr rats that will be used sequentially manifest our radiation endpoints of interest, allowing the sequential study in the same irradiated animals of GI-ARS (project 1), lung and kidney damage (project 2) and cardiovascular damage (project 3). Each project also features state-of-the-art pharmaceutical mitigators that have already been designed and tested by the relevant project team, using conventional x rays for their respective endpoint. The proposal also features three strong central research cores (radiation, biomarker and statistics), unifying the research program. The 7 project and core teams already have a strong track record of working together, with >260 team-team interactions in publications, and >50 team-team interactions in grants - largely from niaid rncp grants. Finally a highly experienced administrative core will provide fiscal management support and will organize an annual 1.5-day retreat, coupled with a full-day training session targeting junior radiation scientists.

Transactions

Action Obligated Date
Amendment $3,250,000
Original award $3,194,030

Subawards

Subrecipient Amount Awarded
The Medical College Of Wisconsin, Inc. for medical countermeasures (MCM) for the treatment of radiation damage to the lung and kidney. Our group at the Medical College of Wisconsin (MCW) has… $525,206
The Medical College Of Wisconsin, Inc. The Medical College of Wisconsin, Inc. will support the MERIE Radiation, Animal, and Dosimetry Core. Dr. Eenas Omari and Dr. Eric Jensen will provide… $15,840
University Of Arkansas For Medical Sciences Board of Trustees of the University of Arkansas acting for and on behalf of the University of Arkansas for Medical Sciences will support the MERIE Project 3… $480,765
University Of Arkansas For Medical Sciences Board of Trustees of the University of Arkansas acting for and on behalf of the University of Arkansas for Medical Sciences will support the MERIE Statistical… $59,679
Nelson Scientific Labs LLC Nelson Scientific Labs, LLC will support the MERIE project by analyzing metabolomics, lipidomics, and proteomics data generated for Projects 1, 2, and 3. Dr.… $142,579
Georgetown University Georgetown University will support the MERIE project by leading the omics core under Dr. Amrita Cheema. Georgetown will coordinate with project leaders for… $306,640

Quick answers

Who received award P01AI186817?

P01AI186817 was awarded to The Trustees Of Columbia University In The City Of New York by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 26, 2025.

How much is award P01AI186817 worth?

$6,444,030 has been obligated on P01AI186817.

Which agency awarded P01AI186817?

National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded P01AI186817, with funding from Office of the Director (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award